
    
      The aim of the research is to study the activity of PD-1 inhibitors in patients with
      metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have
      already received the authorities approvals. The data collected will be crucial for the
      understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
    
  